Rosetta Genomics, a developer of therapeutic products based on newly discovered genes, filed for an IPO on Friday. The Israel-based company plans to offer 3 million shares at a range of $11-$13. The deal has a proposed market cap of $136 million. CE Unterberg Towbin, Oppenheimer & Co. and Maxim Group LLC are set to manage the deal. Timing has yet to be announced.
